Structured evidence table for Cacao Flavanol Visual Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Cacao Flavanol Visual Performance Randomized Trial | It includes increased interferons, tumor necrosis factor, bradykinin, serine proteases, and soluble thrombomodulin, and altered clot lysis times [,,,,], all of which contribute to microvascular and thrombotic disease [,]. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Visual Performance Randomized Trial | A myriad of causes can trigger fatigue, but its development has been strongly associated with post-viral phases of infection. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Visual Performance Randomized Trial | Long COVID-associated fatigue has been causally linked to sustained inflammation and to endothelial and mitochondrial dysfunction. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Visual Performance Randomized Trial | 1 2 3 4 5 6 7 8 Coronavirus disease 2019 (COVID-19) is caused by the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Visual Performance Randomized Trial | 6 2,7–9 10 11 12 13 Although amyloid-beta and tau hypotheses have been the primary hypotheses in the underlying pathogenesis of AD, emerging evidence suggests that amyloidegenesis can be exacerbated by oxidative stress, leading to AD development and progression []. | 3 | Zainuddin Muhammad-Safuan (2026) | Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives |
| Cacao Flavanol Visual Performance Randomized Trial | Growing evidence suggests that oxidative stress and impairment of innate antioxidative defence may precede the pathological features of AD and clinical manifestations [,]. | 3 | Zainuddin Muhammad-Safuan (2026) | Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives |
| Cacao Flavanol Visual Performance Randomized Trial | Therefore, this review aims to highlight evidence of oxidative biomarkers across different specimens, including post-mortem brain and biofluids in AD patients compared to the healthy population. | 3 | Zainuddin Muhammad-Safuan (2026) | Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives |
| Cacao Flavanol Visual Performance Randomized Trial | 1 1 2 1 3 4 5 Alzheimer's disease (AD) is the most prominent age-related neurodegenerative disease in the world []. | 3 | Zainuddin Muhammad-Safuan (2026) | Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives |
Source documents